CSBio CSBio

X
[{"orgOrder":0,"company":"LG Chem","sponsor":"UNICEF","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"LG Chem to Supply UNICEF with $200 Million Worth of Essential Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"LG Chem"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Regulatory Approval of COVID-19 Vaccine SKYCovion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Chemicals"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"SK Bioscience"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gc Biopharma'S \"GC Flu\" Obtains Vaccine Approval in Egypt: First-Ever Approval of the Company's Quadrivalent Flu Vaccine on the African Continent","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"GC Biopharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"EuBiologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"GC Biopharma"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Reports Progress in Phase 3 Trial of COVID-19 Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion\u2019s Monoclonal Antibody Treatment For COVID-19, Regdanvimab (CT-P59) Becomes the First Authorized COVID-19 Treatment Approved from The Korean Ministry of Food and Drug Safety (MFDS)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion\u2019s Monoclonal Antibody Treatment Regdanvimab, Approved by the European Commission for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 Antibody Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Samsung Biologics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and AstraZeneca Expand Strategic Manufacturing Partnership to Include COVID-19 and Cancer Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The agreement aims to produce cholera vaccines including, Euvichol, an oral cholera vaccine for the prevention of cholera, a disease that is prevalent mainly in the developing countries.

            Lead Product(s): Euvichol

            Therapeutic Area: Infections and Infectious Diseases Product Name: Euvichol

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: EuBiologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GCFLU Quadrivalent (prefilled syringes), immunizing against one more strain of influenza virus subtype B in addition to the two strains of subtype A and another strain of subtype B.

            Lead Product(s): Quadrivalent Influenza Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: GCFLU

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            SKYCovion contains nanoparticles of recombinant Receptor Binding Domain (RBD) of SARS-CoV-2 Spike (S) protein from the parental D614G strain and an adjuvant system (AS03) and got approval by MHRA for treating COVID-19 infection.

            Lead Product(s): Recombinant Adjuvanted Covid-19 Vaccine,AS03

            Therapeutic Area: Infections and Infectious Diseases Product Name: SKYCovion

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.

            Lead Product(s): Sabin Inactivated Polio Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Eupolio

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: UNICEF

            Deal Size: $200.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Sky Zoster vaccine consists live attenuated varicella virus which is administered subcutaneously for the prevention of herpes zoster in adults 50 years of age or older.

            Lead Product(s): Live Attenuated Varicella Virus

            Therapeutic Area: Infections and Infectious Diseases Product Name: Sky Zoster

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Samsung Biologics manufactures AstraZeneca’s COVID-19 long-acting antibody, Evusheld, also known as AZD7442 (tixagevimab, cilgavimab), a combination that provides long-lasting protection for up to 12 months in COVID 19 infection.

            Lead Product(s): Tixagevimab,Cilgavimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Evusheld

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: $380.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership December 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The EC approval is based on the global Phase III clinical trial data which showed that regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72% for patients at high-risk of progressing to severe COVID-19.

            Lead Product(s): Regdanvimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Regkirona

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Regkirona (regdanvimab, also known as CT-P59) is a monoclonal antibody with activity against SARS-CoV-2 used for treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition.

            Lead Product(s): Regdanvimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Regkirona

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the manufacturing services and supply agreement, Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The final stage of human tests of the drug candidate, known as Regkirona or CT-P59, is being conducted in 13 countries, including Korea, the US, Spain and Romania, the firm added. The treatment has cleared an emergency use authorization in Korea in February.

            Lead Product(s): Regdanvimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Regkirona

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY